Malin Corporation

Sharpening the strategic focus

  • Sectors : Pharma and healthcare
  • Companies : Malin Corporation

Ratings and price correct at time of issue.

  • Malin Corporation

    Closing Price: 392c

  • RATING 29/09/15

  • PREVIOUS RATING N/A

DAVY VIEW

Malin is sharpening its strategic focus. It has simplified its strategy to focus on four priority assets that hold considerable upside, and the leaner structure provides a longer operational runway. We think Malin’s fair value (FV) could rise to €690m (a 70% increase from June 2018) by December 2019, driven mainly by Poseida – for which we think a trade sale/IPO is possible. The Capital Markets Day on November 8th should clarify the pathway to value crystallisation. We reiterate our ‘Outperform’ rating with a €15.90 price target.

Download full report with analyst certification and important disclosures

Nov 5 2018, 07:00 GMT

Download